Home » Stocks » MRKR

Marker Therapeutics, Inc. (MRKR)

Stock Price: $3.24 USD 0.01 (0.31%)
Updated Jun 16, 2021 9:43 AM EDT - Market open
Market Cap 295.53M
Revenue (ttm) 466,785
Net Income (ttm) -31.00M
Shares Out 56.47M
EPS (ttm) -0.63
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 16
Last Price $3.24
Previous Close $3.23
Change ($) 0.01
Change (%) 0.31%
Day's Open 3.20
Day's Range 3.20 - 3.28
Day's Volume 46,396
52-Week Range 1.32 - 3.77

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Analysts say these are penny stocks to buy right now & have bullish targets to back it up. The post 5 Penny Stocks Analysts Say To Buy With Targets Up To 219% Right Now appeared first on Penny Stocks to...

Other stocks mentioned: ITRM, SESN, TELL, VTGN
3 weeks ago - PennyStocks

Top penny stocks to buy today? Check these 3 out for your watchlist The post Top Penny Stocks to Buy Today?

Other stocks mentioned: CSCW, OBLN
3 weeks ago - PennyStocks

HOUSTON, May 12, 2021 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies fo...

1 month ago - PRNewsWire

HOUSTON, April 29, 2021 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies ...

1 month ago - PRNewsWire

HOUSTON, April 27, 2021 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies ...

1 month ago - PRNewsWire

Investors need to pay close attention to Marker Therapeutics (MRKR) stock based on the movements in the options market lately.

2 months ago - Zacks Investment Research

Reddit penny stocks continue to be of interest to risky investors and InvestorPlace is looking at the top ones for Monday. The post 10 Reddit Penny Stocks Seeing the Most Chatter Today appeared first on...

Other stocks mentioned: AYTU, BNGO, CTXR, DNN, HOFV, IDEX, NEOS ...
2 months ago - InvestorPlace

Odonate Therapeutics, Inc. (NASDAQ: ODT), Dyadic International, Inc. (NASDAQ: DYAI) and Marker Therapeutics, Inc. (NASDAQ: MRKR) are among the early biotech movers in Monday's session. Odonate to Shut S...

Other stocks mentioned: DYAI, ODT
2 months ago - Benzinga

Biotech stocks reversed course in the week ended March 19 amid mixed news flow on data readouts and lackluster broader market performance. Rubius Therapeutics, Inc. (NASDAQ: RUBY) was among the biggest ...

Other stocks mentioned: BMY, PFE, BCRX, PCRX, PRQR, RUBY, ZEAL
2 months ago - Benzinga

Clovis Oncology, Inc. (NASDAQ: CLVS), Marker Therapeutics, Inc. (NASDAQ: MRKR) and Alector, Inc. (NASDAQ: ALEC) are among the biggest biotech gainers Friday. Clovis Jumps On Ovarian Cancer Data: Clovis ...

Other stocks mentioned: ALEC, CLVS
2 months ago - Benzinga

HOUSTON, March 16, 2021 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies...

2 months ago - PRNewsWire

HOUSTON, March 15, 2021 /PRNewswire/ --  Marker Therapeutics, Inc.  (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapie...

3 months ago - PRNewsWire

Marker Therapeutics Inc (NASDAQ: MRKR) priced an underwritten public offering of 28.57 million common shares at $1.75 per share, representing a 31% discount from the last close price of $2.53 on Thursda...

3 months ago - Benzinga

HOUSTON, March 12, 2021 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies...

3 months ago - PRNewsWire

HOUSTON, March 11, 2021 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies...

3 months ago - PRNewsWire

HOUSTON, March 9, 2021 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies f...

3 months ago - PRNewsWire

HOUSTON, Jan. 13, 2021 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies f...

5 months ago - PRNewsWire

Cyclo Therapeutics (NASDAQ: CYTH) shares are trading higher Tuesday after the company announced "positive" efficacy data from an extension protocol with Trappsol Cyclo in patients with Niemann-Pick Dise...

Other stocks mentioned: VVOS, THC, CYTH
5 months ago - Benzinga

HOUSTON, Jan. 5, 2021 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies fo...

5 months ago - PRNewsWire

Marker Therapeutics, Inc. (MRKR) CEO Peter Hoang on Q3 2020 Results - Earnings Call Transcript

7 months ago - Seeking Alpha

HOUSTON, Nov. 9, 2020 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies fo...

7 months ago - PRNewsWire

HOUSTON, Sept. 17, 2020 /PRNewswire/ -- Marker Therapeutics, Inc.

8 months ago - PRNewsWire

HOUSTON, Aug. 10, 2020 /PRNewswire/ -- Marker Therapeutics, Inc.

10 months ago - PRNewsWire

HOUSTON, June 30, 2020 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies ...

11 months ago - PRNewsWire

HOUSTON, June 23, 2020 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies f...

11 months ago - PRNewsWire

Marker Therapeutics, Inc. (MRKR) CEO Peter Hoang on Q1 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Even in turbulent times, technical analysis helps pinpoint penny stocks that may be oversold and due for a positive trend reversal.

Other stocks mentioned: BW, CTEK, SONG, WBT
1 year ago - Investopedia

The Food and Drug Administration (FDA) on Friday issued emergency use authorizations to blood purification devices manufactured by Terumo Corp. and Marker Therapeutics Inc.

Other stocks mentioned: TRUMY
1 year ago - Market Watch

Marker Therapeutics' (MRKR) CEO Peter Hoang on Q3 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Marker reports positive positive preliminary results in a phase 1/2 study using MultiTTA to treat patients with pancreatic cancer.

1 year ago - Seeking Alpha

Marker Therapeutics' MultiTAA cell therapy has many advantages over other currently available therapies like CAR-T and TCR; most notable was the observation of epitope spreading which was an unexpected ...

1 year ago - Seeking Alpha

As of late, it has definitely been a great time to be an investor Marker Therapeutics.

2 years ago - Zacks Investment Research

MARKER THERAPEUTICS, INC. (MRKR) delivered earnings and revenue surprises of 7.69% and -100.00%, respectively, for the quarter ended March 2019.

2 years ago - Zacks Investment Research

An abstract detailing one of the company's clinical programs was rejected from an important industry meeting.

2 years ago - The Motley Fool

About MRKR

Marker Therapeutics, Inc., a clinical stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. Its MultiTAA-specific T cell technology is based on the expansion of non-engineered tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment... [Read more...]

Industry
Biotechnology
CEO
Peter Hoang
Employees
44
Stock Exchange
NASDAQ
Ticker Symbol
MRKR
Full Company Profile

Financial Performance

In 2020, MRKR's revenue was $466,785, an increase of 118.95% compared to the previous year's $213,194. Losses were -$28.71 million, 34.0% more than in 2019.

Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for MRKR stock is "Buy." The 12-month stock price forecast is 6.50, which is an increase of 100.93% from the latest price.

Price Target
$6.50
(100.93% upside)
Analyst Consensus: Buy